Effectiveness of targeting HER2 in heavily pretreated patients with occult HER2-positive (tissue-negative, serum-positive and/or HER2-positive circulating tumor cells) metastatic breast cancer in the clinical routine.

Tumor Cells ◽

Circulating Tumor Cells ◽

Metastatic Breast ◽

Her2 Positive ◽

Clinical Routine ◽

Heavily Pretreated ◽

Pretreated Patients

Circulating tumor cells (CTCs) and cytokeratin 19 (CK19) mRNA as prognostic factors in heavily pretreated patients with metastatic breast cancer

Cancer Treatment and Research Communications ◽

10.1016/j.ctarc.2018.04.003 ◽

2018 ◽

Vol 16 ◽

pp. 13-17

Author(s):

S. Morales ◽

A. Velasco ◽

A. Gasol ◽

F. Córdoba ◽

J. Vidal ◽

...

Keyword(s):

Breast Cancer ◽

Prognostic Factors ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Metastatic Breast ◽

Cytokeratin 19 ◽

Ck19 Mrna ◽

Heavily Pretreated ◽

Pretreated Patients

Targeting HER2 in patients with HER2-negative metastatic breast cancer with elevated serum levels of the HER2 extracellular domain and/or HER2-positive circulating tumor cells in the clinical routine

Annals of Oncology ◽

10.1093/annonc/mdv115.08 ◽

2015 ◽

Vol 26 ◽

pp. iii6

Author(s):

C.M. Kurbacher ◽

A. Quade ◽

G. Kunstmann ◽

S. Herz ◽

J.A. Kurbacher ◽

...

Keyword(s):

Breast Cancer ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Elevated Serum ◽

Metastatic Breast ◽

Serum Levels ◽

Extracellular Domain ◽

Her2 Positive ◽

Clinical Routine

Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study

Breast Cancer Research and Treatment ◽

10.1007/s10549-012-2045-1 ◽

2012 ◽

Vol 134 (1) ◽

pp. 283-289 ◽

Cited By ~ 70

Author(s):

Marta Pestrin ◽

Silvia Bessi ◽

Fabio Puglisi ◽

Alessandro M. Minisini ◽

Giovanna Masci ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Single Agent ◽

Metastatic Breast ◽

Proof Of Concept ◽

Her2 Positive ◽

Multicenter Phase

OT1-02-06: DETECT III – A Multicenter, Randomized, Phase III Study To Compare Standard Therapy Alone Versus Standard Therapy Plus Lapatinib in Patients with Initially HER2−Negative Metastatic Breast Cancer and HER2−Positive Circulating Tumor Cells.

10.1158/0008-5472.sabcs11-ot1-02-06 ◽

2011 ◽

Cited By ~ 1

Author(s):

CA Melcher ◽

W Janni ◽

U Ortmann ◽

B Jäger ◽

B Rack ◽

...

Keyword(s):

Breast Cancer ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Standard Therapy ◽

Metastatic Breast ◽

Phase Iii ◽

Her2 Positive ◽

Phase Iii Study

PD05-07: Prospective Validation and Characterization of HER2 Positive Circulating Tumor Cells in Patients with HER2 Negative Metastatic Breast Cancer.

10.1158/0008-5472.sabcs11-pd05-07 ◽

2011 ◽

Author(s):

EM Olson ◽

LM Flores ◽

JS Najita ◽

C Curley ◽

J Jeong ◽

...

Keyword(s):

Breast Cancer ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Metastatic Breast ◽

Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker

BMC Cancer ◽

10.1186/1471-2407-13-202 ◽

2013 ◽

Vol 13 (1) ◽

Cited By ~ 41

Author(s):

Yi Liu ◽

Qian Liu ◽

Tao Wang ◽

Li Bian ◽

Shaohua Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Metastatic Breast ◽

Predictive Biomarker ◽

Breast Cancer Patients ◽

Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer

International Journal of Clinical Oncology ◽

10.1007/s10147-011-0260-0 ◽

2011 ◽

Vol 17 (2) ◽

pp. 96-104 ◽

Cited By ~ 54

Author(s):

Naoki Hayashi ◽

Seigo Nakamura ◽

Yasuharu Tokuda ◽

Yuji Shimoda ◽

Hiroshi Yagata ◽

...

Keyword(s):

Breast Cancer ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Prognostic Value ◽

Metastatic Breast ◽

Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy

Annals of Oncology ◽

10.1093/annonc/mdr434 ◽

2012 ◽

Vol 23 (5) ◽

pp. 1144-1150 ◽

Cited By ~ 67

Author(s):

A. Giordano ◽

M. Giuliano ◽

M. De Laurentiis ◽

G. Arpino ◽

S. Jackson ◽

...

Keyword(s):

Breast Cancer ◽

Targeted Therapy ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Metastatic Breast ◽

P1-06-12: Circulating Tumor Cells (CTC) Monitoring during Phase II Study with Lapatinib (L) and Capecitabine (C) in Patients with Brain Metastases from HER2−Positive (+) Metastatic Breast Cancer (MBC) before Whole Brain Radiotherapy (WBR): LANDSCAPE Study.

10.1158/0008-5472.sabcs11-p1-06-12 ◽

2011 ◽

Author(s):

J-Y Pierga ◽

C Cropet ◽

P Tresca ◽

F Dalenc ◽

G Romieu ◽

...

Keyword(s):

Breast Cancer ◽

Brain Metastases ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Phase Ii Study ◽

Metastatic Breast ◽

Whole Brain Radiotherapy ◽

Her2 Positive ◽

Brain Radiotherapy

Abstract P3-01-08: HER2-negative metastatic breast cancer with HER2-positive circulating tumor cells (CTCs): A new CTC-defined HER2-positive subgroup

10.1158/1538-7445.sabcs18-p3-01-08 ◽

2019 ◽

Author(s):

AN Shah ◽

L Gerratana ◽

Q Zhang ◽

AA Davis ◽

Y Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Metastatic Breast ◽